Getinge AB
Getinge AB is a global technology company, headquartered in Sweden, that stands as a foundational leader in the Extracorporeal Membrane Oxygenation (ECMO) market, primarily through its Acute Care Therapies segment (which includes its Maquet brand). The company provides comprehensive ECMO solutions, including both machines and disposables, renowned for reliability and scalability in critical care. Getinge’s core offerings include advanced ECLS systems like the compact, versatile, and transport-approved **Cardiohelp II** and the in-hospital **Rotaflow II System**. These platforms feature robust pump performance and integrated monitoring, designed to be user-friendly while ensuring safety and efficiency in critical settings. Getinge focuses on continuous innovation to improve oxygenator efficiency, such as its Quadrox Oxygenators, and minimize complications, positioning it as a key provider of end-to-end extracorporeal life support for patients with severe cardiac and respiratory failure, including conditions like ARDS and COVID-19.
Medtronic plc
Medtronic plc, a global medical device company based in Ireland, has established a powerful presence in the ECMO market by leveraging its extensive expertise in cardiopulmonary support and advanced perfusion technologies. The company is recognized as a top-three player, offering a diverse portfolio of life-support technologies, including its **VitalFlow™ ECMO System** and oxygenation systems like the **Affinity®** and **Minimax®** lines. Medtronic’s strategy involves integrating its ECMO platforms seamlessly with its broader cardiovascular and critical care solutions, creating a unified ecosystem for hospitals. Key product components include the **Nautilus™ ECMO Oxygenator** and a range of specialized catheters, such as the Crescent™ Dual-Lumen Catheter. Medtronic’s focus is on engineering advancements like biocompatible coatings and advanced monitoring features to enhance patient safety, reduce clotting risks, and deliver reliable, technologically advanced ECMO solutions globally.
LivaNova PLC
LivaNova PLC is a medical device company, headquartered in the United Kingdom, that is a leading player in the ECMO market, particularly noted for its perfusion technology and Advanced Circulatory Support segment. LivaNova provides sophisticated, integrated ECMO systems and disposables, designed primarily for treating acute cardiac and respiratory failure. Its competitive advantage stems from proprietary innovations like the **EOS ECMO® oxygenator**, which is optimized for extended procedures, and its comprehensive perfusion tubing systems. The company strengthened its portfolio by acquiring ALung Technologies Inc., a provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies. Furthermore, LivaNova’s commitment to next-generation technology is exemplified by the FDA clearance of its advanced circulatory support system, **LifeSPARC**, solidifying its position as a major provider of safe and reliable life support solutions.
Fresenius Medical Care (Xenios/Novalung)
Fresenius Medical Care AG & Co. KGaA, a German global healthcare giant, is a prominent player in the ECMO market through its subsidiary, **Xenios AG**. Xenios, acquired in 2016, is a technology leader specializing in heart and lung assist. The company offers modular and integrated ECMO treatments for patients suffering from cardiac and/or pulmonary failure. The key product is the **Novalung System**, which is notable as the first US FDA–cleared ECMO system for long-term use (more than 6 hours) across VA, VV, and ECPR modalities. The Novalung system is celebrated for its safety, intuitive user interface for simplified workflow, and portability. By leveraging Fresenius Medical Care’s extensive global presence and dedication to advancing critical care, Xenios ensures that its intelligent, patient-centric ECMO solutions are widely accessible and supported by robust clinical education.
Terumo Corporation
Terumo Corporation, a Japanese global medical device company, is a significant provider in the ECMO market, excelling in high-performance circulatory support. Leveraging its deep specialization in cardiovascular systems and cardiopulmonary bypass technologies, Terumo offers a diverse portfolio of ECMO products to healthcare providers worldwide. The company’s focus on continuous R&D results in the use of next-generation membrane materials and sophisticated centrifugal pump designs, which are engineered to enhance patient outcomes, particularly by reducing inflammatory risks and improving efficiency. Terumo’s established presence and strong collaborations, particularly across the Asia-Pacific and EMEA regions, allow it to effectively navigate diverse regulatory landscapes and deliver innovative, adaptive ECMO solutions that align with the growing global need for advanced extracorporeal life support.
Nipro Corporation
Nipro Corporation, headquartered in Japan, is a key manufacturer and supplier in the ECMO market, leveraging its broad portfolio in medical devices, pharmaceuticals, and pharma packaging. The company’s strength in the ECMO space comes from its established expertise in cardiopulmonary and renal care products, which are foundational to extracorporeal circuits. Nipro provides essential components, including high-quality oxygenators, bloodlines, and other critical consumables, that integrate into ECMO systems globally. Its vast production capabilities and expansive distribution network enable it to serve the growing demand in major markets across Japan, the Americas, Europe, and Asia. Nipro’s commitment to manufacturing high-quality, reliable medical instruments reinforces its role in providing the core technological elements necessary for safe and effective ECMO therapy.
MicroPort Scientific Corporation
MicroPort Scientific Corporation, a global medical device company from China, significantly strengthened its position in the Extracorporeal Life Support (ECLS) and ECMO market through strategic acquisitions. In October 2021, MicroPort acquired the German company **Hemovent GmbH**, integrating its advanced ECLS technology. Hemovent’s key offering is a compact, portable ECMO unit that is highly suitable for emergency medicine and patient transport, simplifying setup and deployment outside of traditional Intensive Care Unit (ICU) environments. By incorporating this innovative, patient-centric technology, MicroPort is focused on expanding its critical care portfolio with solutions that provide rapid, effective deployment and enhance patient safety and mobility, establishing itself as a significant and innovative competitor in the global ECMO landscape.
Abbott Laboratories
Abbott Laboratories, a prominent global healthcare company, is recognized as a key player in the ECMO machines market, integrating extracorporeal support into its broad medical device and diagnostics portfolio. Abbott’s involvement is driven by its strong focus on cardiovascular and critical care solutions, aiming to provide comprehensive support for patients with severe heart and lung conditions. While specific full ECMO machine systems are less emphasized than components, its expertise in miniaturized, high-precision diagnostics and cardiac devices means it supplies critical, advanced elements and solutions that interface with the overall ECMO circuit. Abbott’s global presence and continuous investment in medical technology underscore its commitment to delivering high-quality, reliable products essential for enhancing clinical precision and improving patient outcomes in critical care settings.
EUROSETS S.r.l.
EUROSETS S.r.l., a medical device company based in Italy, is an innovative and important developer of advanced extracorporeal life support systems, including ECMO. The company is noted for its focus on new technology in pump design and system integration. In January 2021, EUROSETS commercially released **ECMOLife**, its flagship extracorporeal life support system, which features a magnetic levitation centrifugal pump. This advanced magnetic levitation technology is designed to minimize blood trauma and improve the overall lifespan and safety of the ECMO circuit. EUROSETS S.r.l. is committed to developing state-of-the-art, user-friendly solutions that enhance the efficiency and precision of extracorporeal circulation, validating its position as a key innovator in the specialized critical care market.
Abiomed (Johnson & Johnson MedTech)
Abiomed, a company now within **Johnson & Johnson MedTech** (J&J), entered the ECMO market with the strategic acquisition of Breethe in May 2020. This move was part of J&J MedTech’s broader effort to expand its Heart Recovery portfolio for cardiovascular and critical care. Breethe developed a portable Extracorporeal Membrane Oxygenation system, which complements Abiomed’s core business in circulatory support, particularly the Impella heart pump. By integrating ECMO technology, Abiomed and J&J MedTech are able to offer a more comprehensive set of solutions for patients with life-threatening heart and lung failure. Their focus is on developing miniaturized and easily deployable ECLS systems that enhance patient mobility and care options, strengthening their role as a global leader in advanced circulatory restoration.